-
Migraine patients show impairment in the processing of global visual features, compared with controls, both between and immediately after an attack. The pattern of ictal-interictal potential as noted on magnetoencephalography studies can characterize different migraine types.
-
It has been well recognized that a peak in stroke onset occurs during the early morning hours. This possible circadian periodicity is not well understood, and may in part represent stroke onset earlier during the night that goes unrecognized until the patient arouses.
-
Therapeutic hypothermia after cardiac arrest makes prediction of prognosis more difficult, and neuron-specific enolase measurements add an additional objective test to help determine outcome.
-
A few years ago, vitamin E was deemed to be an extremely important nutrient required to maintain health, prevent or delay several disorders, and prolong life. However, many clinical trials involving intervention with supplemental administration of vitamin E failed to establish or confirm these benefits. A similar prominence is being afforded at present to vitamin D because of relationships being documented between vitamin D deficiency and multiple outcomes, including several disorders and mortality.
-
-
Screening for lung cancer by means of chest X-ray (CXR) does not reduce mortality, even with the addition of sputum cytology.
-
The use of aspirin for the primary prevention of cardiovascular (CV) disease remains controversial.
-
Interpret the rhythm strip shown above. Does it represent complete (3rd degree) AV Block? How would you proceed clinically?
-
A randomized, controlled trial of persons with new onset common cold showed modest effects of placebo on duration and severity of the cold symptoms, but greater effects among the patients who believe in the benefits of echinacea, whether receiving the supplement or placebo.
-
The FDA has approved a second three-drug fixed combination for the treatment of HIV-1 infections. This combination contains two nucleoside analog HIV-1 reverse transcriptase inhibitors (emtricitabine and tenofovir) and a non-nucleoside reverse transcriptase inhibitor (NNRTI; rilpivirine).
